Clinical Trials
Breakthrough Status for Dizal’s Sunvozertinib
OPN is excited that the FDA has granted breakthrough status to Dizal’s Sunvozertinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). OPN is offering access to this breakthrough product by enrolling patients in this DZ2022E0005 trial. This study now open and accruing to gain full FDA approval. The FDA’s Breakthrough Therapy … Continued